Zhang Z, et al. - Among chronic hepatitis B (CHB) patients, researchers evaluated the effectiveness of tenofovir (TDF) monotherapy vs entecavir (ETV) monotherapy by analyzing their long-term clinical outcomes in decreasing incidence of hepatocellular carcinoma (HCC). This research included seven articles with 3,698 patients, 1,574 in the TDF group and 2,124 in the ETV group. According to this meta-analysis, TDF monotherapy reduced the incidence of HCC vs ETV monotherapy in CHB patients; there was no significant differences in the incidence of death or transplantation, encephalopathy or variceal bleeding, indicating that TDF monotherapy may be superior to ETV monotherapy in CHB patients.